🇺🇸 Locatop@ in United States
14 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 14
Most-reported reactions
- Interstitial Lung Disease — 7 reports (50%)
- Cardiopulmonary Failure — 1 report (7.14%)
- Chronic Obstructive Airways Disease Exacerbated — 1 report (7.14%)
- Eczema — 1 report (7.14%)
- Erysipelas — 1 report (7.14%)
- Oedema Peripheral — 1 report (7.14%)
- Osteonecrosis — 1 report (7.14%)
- Rash Erythematous — 1 report (7.14%)
Other Dermatology approved in United States
Frequently asked questions
Is Locatop@ approved in United States?
Locatop@ does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Locatop@ in United States?
Pierre Fabre Medicament is the originator. The local marketing authorisation holder may differ — check the official source linked above.